Abstract
Introduction: Hydroxychloroquine (HCQ)/Chloroquine (CQ) has been evaluated for treatment and prophylaxis against SARS-CoV-2 infection in various studies with conflicting results. We performed a systematic review to synthesize the currently available evidence over the efficacy and safety of HCQ/CQ therapy alone against SARS-CoV-2 infection.
Methods: We searched Embase, PubMed, Web of Science, and Cochrane central for randomized controlled trials (RCTs) and prospective cohort studies published until October 15, 2020 and assessing the efficacy of HCQ alone against SARS-CoV-2 infection. We included studies evaluating HCQ/CQ alone as intervention and placebo/standard care as a control group. Retrospective studies and studies using other drugs (namely azithromycin, corticosteroids, immunomodulators, etc.) we excluded. Thirteen RCTs and three prospective cohort studies were included in this review. We pooled data using a random-effect model.
Results: Pooled data from 12 studies (9917 participants) showed that HCQs increase mortality as compared to placebo/standard of care (RR 1.10; 95% CI:1.00-1.20). Hydroxychloroquine did not reduce the need for hospitalization in out-patients (RR 0.57; 95% CI 0.31-1.02). HCQ group has a significantly higher rate of any adverse event (RR 2.68; 95% CI 1.55-4.64), as compared to the control group. Also, using HCQ for prophylaxis against SARS-CoV-2 infection did not reduce the risk of acquiring SARS-CoV-2 infection (RR 1.04; 95% CI 0.58-1.88).
Conclusions: HCQ therapy for COVID-19 is associated with an increase in mortality and other adverse events. The negative effects are more pronounced in hospitalized patients. Therefore, with the available evidence, HCQ should not be used in prophylaxis or treatment of patients with COVID-19.
Keywords: COVID-19; Coronavirus; Mortality; Prophylaxis; Therapy.
【저자키워드】 COVID-19, coronavirus, therapy, Mortality, Prophylaxis, 【초록키워드】 Randomized controlled trial, Treatment, Efficacy, Corticosteroids, therapy, Randomized controlled trials, Chloroquine, Azithromycin, Hydroxychloroquine, Hospitalization, SARS-COV-2 infection, systematic review, risk, Intervention, drug, hospitalized patients, prospective cohort study, RCT, Prophylaxis, adverse events, immunomodulators, adverse event, Efficacy and safety, HCQ, Care, RCTs, Evidence, Web of Science, Participants, control group, 95% CI, Effect, HCQ therapy, performed, evaluated, searched, increase in, significantly higher, excluded, did not reduce, patients with COVID-19, 【제목키워드】 Meta-analysis, SARS-CoV-2, hydroxychloroquine/chloroquine,